irofulven
Small moleculeexperimental
Irofulven or 6-hydroxymethylacylfulvene is an experimental antitumor agent. It belongs to the family of drugs called alkylating agents. — Wikipedia
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 30, 2018 (NCT03643107)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- DNADEGRADER
DNA degrader
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaIrofulven ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03643107 | Phase 2 | Sep 30, 2018 | Oncology Venture, Smerud Medical Research Denmark |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Oncology Venture | For profit | 1 | 1 | 1 | 2018 |
| Smerud Medical Research Denmark | For profit | 1 | 0 | 1 | 2018 |
2 organizations
Page 1 / 1